KR20180000586A - A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating metabolic disease - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating metabolic disease containing a germinated soybean embryo extract or a fraction thereof, a method for preventing or treating metabolic disease including a step for injecting the composition into an individual other than human, a food composition for preventing or ameliorating metabolic disease containing the germinated soybean embryo extract or the fraction thereof, and a feed composition. The germinated soybean embryo extract is involved in lipid metabolism which increases the number of high-density lipoprotein (HDL), and removes unnecessary cholesterol in body, thereby being useful for preventing or treating metabolic disease caused by abnormal lipid metabolism.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases including a germinated germ extract of soybean germ,

The present invention relates to a pharmaceutical composition for preventing or treating a metabolic disease comprising a soybean germinated embryo extract, more specifically, the present invention relates to a pharmaceutical composition for preventing or treating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof, A method for preventing or treating a metabolic disease comprising administering a composition to a subject other than a human, a food composition for preventing or ameliorating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof, and a feed composition.

Metabolic diseases are diseases caused by metabolism disorders in the body, such as diabetes, gout, cardiovascular disease or dyslipidemia. Among the metabolic diseases, cardiovascular diseases include heart related diseases (myocardial infarction, hypertension, heart failure, arrhythmia, arteriosclerosis) and vascular diseases (stroke, peripheral vascular diseases), and according to the statistics of the World Health Organization (WHO) The incidence and prevalence of cardiovascular disease have been reported to have steadily increased over the last 30 years.

The main causes of these cardiovascular diseases are increased blood cholesterol and changes in blood components due to changes in lipid composition. If the blood flow is not smooth due to the narrowing of the blood vessel due to atherosclerosis due to an increase in cholesterol, sufficient oxygen is not supplied to the brain or heart, and the thrombus formed during bleeding blocks the coronary artery or fine blood vessels Brain or cardiovascular disease. Most of these diseases require lifelong treatment because of the high risk of recurrence.

Accordingly, it is urgently required to develop a therapeutic agent having low toxicity and side effects. Recently, alternative therapies using various active ingredients derived from natural products such as herbal medicines and foods or methods for producing various extracts have been developed. Examples thereof include a pharmaceutical composition for prevention and treatment of cardiovascular diseases (Korean Patent Laid-Open Publication No. 2015-0084405) including wood extracts, or an artificial blood sugar composition for treating hyperlipemia (Korean Patent Laid-Open Publication No. 2015-0064400) It has been developed. However, the development of a natural pharmaceutical composition or a raw material thereof which has superior therapeutic effect and less side effects than the conventional synthetic pharmaceutical composition for the metabolic diseases has not been developed yet.

On the other hand, cholesterol is classified into triglyceride, low density lipoprotein (LDL) cholesterol and high density lipoprotein (HDL) cholesterol depending on the degree of binding with the protein in the blood. LDL-cholesterol is cholesterol that is produced in the liver and transferred to the body, and is a cholesterol that causes arteriosclerosis or heart disease. In contrast, the remaining cholesterol produced by each cell is transferred to the liver, which is called HDL-cholesterol. Since HDL-cholesterol plays a role in eliminating cholesterol in the blood, high levels of HDL-cholesterol reduce the risk of coronary artery disease or heart disease. Triglyceride is a kind of fat in the blood of our body. People with high triglycerides usually have high LDL-cholesterol, and high triglycerides increase the risk of heart attack or stroke.

Under these circumstances, the present inventors have made intensive research to develop a therapeutic agent for a metabolic disease using a component derived from a natural product. As a result, it has been found that an extract of a soybean germinated embryo produced by germinating an abandoned soybean embryo in the process of producing a processed product using soybean, The present inventors have completed the present invention by confirming that cholesterol is increased and unnecessary cholesterol is eliminated in vivo.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof.

Another object of the present invention is to provide a method for the prevention or treatment of metabolic diseases comprising the step of administering the composition to an individual other than a human.

It is another object of the present invention to provide a food composition for preventing or ameliorating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof.

It is another object of the present invention to provide a feed composition for preventing or ameliorating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof.

One aspect for achieving the above object is to provide a pharmaceutical composition for preventing or treating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof.

The term "soybean germinated embryo" of the present invention means a germinated embryo obtained by germinating an embryo isolated from soybean. A method for producing a soybean germinated embryo has been known from previous studies of the present inventors (Korean Laid-Open Patent Application No. 2013-0057173). Specifically, the soybean germinated embryo may be obtained by germinating an embryo isolated from soybean, But is not limited thereto. The therapeutic effect of the germinated germ extract of the present invention on metabolic diseases has not been known at all and has been first identified by the present inventors.

The soybean germinated embryo extract of the present invention may be obtained by extracting the soybean germinated embryo with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.

The term "extract " of the present invention means an extract obtained by extracting a soybean germinated embryo, a diluted solution or concentrate of the extract, a dried product obtained by drying the extract, a preparation or a purified product of the extract, Extracts themselves and extracts of all formulations which can be formed using extracts.

In the soybean germinated embryo extract of the present invention, the method for extracting the soybean germinated embryo is not particularly limited and may be carried out according to a method commonly used in the art. Non-limiting examples of the extraction method include hydrothermal extraction, ultrasonic extraction, filtration, and reflux extraction. These may be performed alone or in combination with two or more methods.

In the present invention, the kind of the extraction solvent used for extracting the soybean germinated embryo is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water, alcohol, and a mixed solvent thereof. These solvents may be used alone or in combination. When an alcohol is used as a solvent, an alcohol having 1 to 4 carbon atoms can be specifically used.

The term "fraction " of the present invention means a product obtained by performing fractionation to separate a specific component or a specific component group from a mixture containing various components.

The fractionation method for obtaining the fraction in the present invention is not particularly limited and may be carried out according to a method commonly used in the art. As a non-limiting example of the above-mentioned fractionation method, there can be mentioned a method of treating a soybean germinated embryo extract of the present invention with a predetermined solvent to obtain a fraction from the extract.

The kind of the fraction solvent used for obtaining the fraction in the present invention is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the fraction solvent include polar solvents such as water and alcohol; And non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of one or more. When an alcohol is used in the fraction solvent, an alcohol having 1 to 4 carbon atoms can be specifically used.

The soybean germinated embryo extract of the present invention may contain soyasaponin.

The term " soyasaponin " of the present invention is a kind of phytosterol contained in soybeans, and it is a phytosterol which is based on aglycone structure such as steroid or triterpenoid, Respectively. Specific examples of the soy saff saponin include Soyasaponin Aa, Soyasaponin Ab, Soyasaponin Ac, Soyasaponin Ae, Soyasaponin Af, Soyasaponin Ba, Soyasaponin Bb, Soyasaponin Bc, Soyasaponin Bd, Soyasaponin Be, Soyasaponin βg, Soyasaponin βa, Ah, soyasaponin gamma g, but is not limited thereto.

Specifically, the Soyasaponin Aa has the molecular formula C ₆₄ H ₁₀₀ O ₃₁ , and has the structure of the following formula (1).

Soyasaponin Ab has the molecular formula C ₆₇ H ₁₀₄ O ₃₃ and has the structure of the following formula (2).

Soyasaponin Ac has the molecular formula C ₆₇ H ₁₀₄ O ₃₂ and has the structure of the following formula (3).

Soyasaponin Ae has the structure of the following formula (4).

Soyasaponin Af has the structure of the following formula (5).

Soyasaponin Ba is selected from the group consisting of Soyasaponin V; And (3beta, 4beta, 22beta) -22,23-Dihydroxy-12-en-3-yl O-beta-D-glucopyranosyl- (1-2) -O-beta-D- galactopyranosyl- beta-D-glucopyranosiduronic acid, has the molecular formula C ₄₈ H ₇₈ O ₁₉ , and has the structure of the following formula (6).

Soyasaponin Bb is also named Soyasaponin I, has the molecular formula C ₄₈ H ₇₈ O ₁₈ , and has the structure of the following formula (7).

Soyasaponin Bc has the structure of the following formula (8).

Soyasaponin Bd has the structure of the following formula (9).

Soyasaponin Be is to have the molecular formula C ₄₉ H ₇₈ O _18, has the structure of formula (10).

Soyasaponin? G has a structure represented by the following formula (11).

Soyasaponin? A has a structure represented by the following formula (12).

Soyasaponin Ag has a structure represented by the following formula (13).

Soyasaponin Ad has the structure of the following formula (14).

Soyasaponin Ah has the structure of the following formula (15).

Soyasaponin? G has a structure represented by the following formula (16).

In one embodiment of the present invention, the soybean germinated embryo extract was applied to an UPLC QTOF-mass spectrometer, and major compounds were selected and found to contain saponin, a saponin-based substance (Table 1).

The soybean germinated embryo extract of the present invention may be one that increases HDL (high density lipoprotein).

The term "HDL (high density lipoprotein) " of the present invention means high density lipoprotein as HDL-cholesterol. Since HDL plays a role in eliminating unwanted cholesterol in vivo, an increase in HDL also reduces the possibility of disease caused by cholesterol.

In the present specification, the HDL and HDL-cholesterol may be used in combination.

In one embodiment of the present invention, the extract was administered to an animal model in which hyperlipemia induced by menopause resulted in a decrease in Total Chol / HDL ratio and Trig / HDL ratio, which are indicators of blood lipid metabolism And 3). This suggests that the extract has an effect of eliminating unnecessary cholesterol in vivo by relating to lipid metabolism which increases the HDL concentration.

The term "metabolic disease" of the present invention means a disease caused by metabolic disorders in vivo. The metabolic diseases include, but are not limited to, cardiovascular diseases, dyslipidemia, diabetes, . Among these diseases, cardiovascular diseases and dyslipidemia are caused by abnormality of lipid metabolism, diabetes is caused by abnormality of saccharide object, and gout is known to be caused by abnormality of uric acid metabolism.

For the purpose of the present invention, the soybean germinated embryo extract is not particularly limited, but it may exhibit a therapeutic effect on a metabolic disease caused by abnormality of lipid metabolism among the various metabolic diseases.

The term "cardiovascular disease" of the present invention means a disease that occurs in the heart and major arteries. The cardiovascular disease is mainly caused by a disorder of the blood circulation, and cholesterol is deposited in the blood vessel, which causes the diameter of the inside of the blood to be narrowed. Specific examples of the cardiovascular diseases include, but are not limited to, hypertension, ischemic heart disease, coronary artery disease, angina pectoris, myocardial infarction, atherosclerosis (arteriosclerosis), cerebrovascular disease or stroke.

The term "dyslipidemia" of the present invention means a state in which total cholesterol, LDL-cholesterol or triglyceride is increased in the blood, or a state in which HDL-cholesterol is decreased. Specific examples include, but are not limited to, hyperlipidemia, hypercholesterolemia or hypertriglyceridemia.

The term "prevention" of the present invention means any action that inhibits or delays the onset of a metabolic disease by administration of a pharmaceutical composition containing the extract of the present invention.

The term "treatment" of the present invention means any suspicion of a metabolic disease by administration of the pharmaceutical composition, and any action that improves or alters the symptoms of an onset.

The pharmaceutical composition of the present invention may contain the extract in an amount of 0.0001 to 50% by weight based on the weight of the total composition, and may include, but is not limited to, 0.01 to 10% by weight.

The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent conventionally used in the production of a pharmaceutical composition, and the carrier may include a non-naturally occuring carrier .

The term "pharmaceutically acceptable" of the present invention means that it exhibits properties that are not toxic to the cells or humans exposed to the composition.

Specifically, the pharmaceutical composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method . In the present invention, the carrier, excipient and diluent which may be contained in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use may include various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc. in addition to water and liquid paraffin, which are simple diluents commonly used in suspension, liquid solutions, emulsions and syrups have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

Another aspect of the present invention provides a method for preventing or treating metabolic diseases, comprising administering the composition to a subject other than a human.

The term "administering" of the present invention means introducing a given substance into an individual in a suitable manner.

The term "individual" of the present invention means all animals including mice, mice, livestock and the like, including humans who have developed or are capable of developing metabolic diseases. As a specific example, it may be a mammal including a human.

The method for preventing or treating a metabolic disease of the present invention specifically includes a step of administering a pharmaceutically effective amount of a pharmaceutical composition for preventing or treating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof to a subject other than a human can do.

The term "pharmaceutically effective amount" of the present invention means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects. The effective dose level is determined by the sex, age And other medical fields, including drugs used in combination or concurrently, with respect to body weight, health status, type of disease, severity, activity of the drug, sensitivity to the drug, method of administration, administration time, route of administration, Can be readily determined by those skilled in the art according to well known factors.

Specifically, the composition of the present invention may be administered at a dose of 0.0001 to 100 mg / kg body weight per day, more specifically 0.001 to 100 mg / kg body weight, based on the solid content. The administration may be such that the recommended dose is administered once a day or divided into several doses.

In the method for the prevention or treatment of metabolic diseases of the present invention, the route of administration and the mode of administration of the composition are not particularly limited, and any route of administration may be used as long as the composition containing the composition can reach the desired site Depending on the mode of administration. Specifically, the composition may be administered orally or parenterally through various routes. Non-limiting examples of routes of administration include oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, Intramuscularly or through inhalation or the like.

Another aspect for achieving the above object is to provide a food composition for preventing or ameliorating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof.

The term "improvement" of the present invention means all the actions for improving or alleviating the metabolic disease upon administration of the composition.

The term "food" of the present invention includes dairy products such as meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, various soups, drinks, tea, , A vitamin complex, a health functional food, and a health food, all of which include foods in a conventional sense.

The term "functional food" as used herein means the same term as "food for special health use" (FoSHU). In addition to nutrition, It means food. Here, the term "function" means that the structure and function of the human body have a beneficial effect for health use such as controlling nutrients or physiological action. The food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients which are conventionally added in the art. In addition, the formulations of the food can also be produced without restrictions as long as they are formulations recognized as food. The composition for food of the present invention can be manufactured in various forms, and unlike general pharmaceuticals, it has the advantage that there is no side effect that may occur when a drug is used for a long period of time, and is excellent in portability, Can be ingested as an adjuvant to enhance the effect of preventing or improving metabolic diseases.

The health food refers to a food having an active health promotion or promotion effect compared with a general food, and a health supplement food refers to a food for health assistance. In some cases, the terms health functional foods, health foods, and health supplements are used.

Specifically, the health functional food is a food prepared by adding the extract of the present invention to food materials such as beverage, tea, spice, gum and confectionery, or by encapsulation, powdering, suspension or the like, But it has the advantage that there is no side effect that can occur when the food is used as a raw material and long-term use of the drug.

Since the food composition of the present invention can be routinely ingested, it can be very usefully used because it can be expected to have a high effect on prevention or improvement of metabolic diseases.

The food composition may further comprise a physiologically acceptable carrier. The type of carrier is not particularly limited, and any carrier conventionally used in the art can be used.

In addition, the food composition may contain additional components that are commonly used in food compositions and can improve odor, taste, visual appearance, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid and the like. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) It may also include amino acids such as lysine, tryptophan, cysteine, valine, and the like.

In addition, the food composition may further contain antiseptic agents (such as potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate), bactericides (Sodium nitrite), bleach (sodium sulfite), seasoning (sodium MSG glutamate, etc.), sweeteners (dicin, cyclamate, saccharin, etc.), coloring agents , Sodium, etc.), perfume (vanillin, lactones, etc.), swelling agents (alum, potassium hydrogen D-tartrate), emulsifiers, thickeners (foams), encapsulating agents, gum bases, foam inhibitors, solvents, And may include food additives. The additives may be selected and used in appropriate amounts depending on the type of food.

The extract of the present invention can be added intact or used together with other food or food ingredients, and can be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the food composition of the present invention may be added in an amount of not more than 50 parts by weight, specifically not more than 20 parts by weight, based on the food or beverage, when the food or drink is prepared. However, in case of long-term ingestion for health and hygiene purposes, the active ingredient may be contained in an amount not exceeding the above range and there is no problem in terms of safety.

As an example of the food composition of the present invention, it can be used as a health beverage composition. In this case, various flavors or natural carbohydrates can be added as an additional ingredient like ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose; Polysaccharides such as dextrin, cyclodextrin; Xylitol, sorbitol, erythritol, and the like. Sweeteners include natural sweeteners such as tau Martin and stevia extract; Synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate may be generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 mL of the health beverage composition of the present invention.

In addition to the above, the health beverage composition may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acid, protective colloid thickener, pH adjuster, stabilizer, Alcohols or carbonating agents, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.

The food composition of the present invention may be contained at various weight percentages as long as it can exhibit a preventive or ameliorative effect of metabolic diseases. Specifically, the extract of the present invention may be contained in an amount of 0.00001 to 100% by weight or 0.01 to 80% by weight, But is not limited thereto.

Another aspect of the present invention provides a feed composition for preventing or ameliorating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof.

The term "feed " of the present invention means any natural or artificial diet, single meal, or the like ingredients for feeding, ingesting, digesting, or suitable for the animal.

The feed may comprise a feed additive or supplementary feed.

The kind of the feed is not particularly limited, and feeds conventionally used in the art can be used. Non-limiting examples of such feeds include vegetable feeds such as cereals, muscle roots, food processing busines logistics, algae, fibers, pharmaceutical buses, oils, fats, pastes or grain by-products; Animal feeds such as proteins, inorganic substances, fats, oils, fats, oils, monocellular proteins, animal plankton or foods. These may be used alone or in combination of two or more.

Since the soybean germinated embryo extract of the present invention participates in lipid metabolism which increases HDL, it removes unnecessary cholesterol in vivo, and thus can be usefully used for the prevention or treatment of metabolic diseases caused by abnormality of lipid metabolism.

FIG. 1 is a graph showing toxicity of soybean germinated embryo extract against hepatocyte HepG2. FIG. Soybean germinated embryo extracts were treated at concentrations of 50, 100, 200, 300, 400 and 500 ㎍ / mL.
FIG. 2 is a graph showing the effect of soybean germinated embryo extract on HDL lipid metabolism, showing the ratio of total cholesterol to HDL. The ovariectomized mouse (OVX) was used as a negative control and the mice were treated with 0.1 mg / kg, 1 mg / kg and 5 mg / kg of soybean germinated embryo extract. Respectively.
FIG. 3 is a graph showing the effect of soybean germinated embryo extract on HDL lipid metabolism, showing the ratio of triglyceride to HDL. The ovariectomized mouse (OVX) was used as a negative control and the mice were treated with 0.1 mg / kg, 1 mg / kg and 5 mg / kg of soybean germinated embryo extract. Respectively.
FIG. 4 is a graph showing the effect of soybean germinated embryo extract on LDL lipid metabolism, showing the ratio of LDL to HDL. The ovariectomized mouse (OVX) was used as a negative control and the mice were treated with 0.1 mg / kg, 1 mg / kg and 5 mg / kg of soybean germinated embryo extract. Respectively.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

Manufacturing example  1. Beans Germination embryo  Preparation of extract

In order to prepare the soybean germinated embryo extract, the soybean germinated embryo prepared according to the previous study of the present inventor was used. Specifically, the soybean embryo was immersed in running water and germinated. After about 24 hours, the soybean germinated embryo was harvested, lyophilized and powdered to obtain a soybean germinated embryo powder. The resulting soybean germinated embryo powder was extracted by adding a fermented syrup, followed by filtration to obtain a liquid component, and the liquid component was freeze-dried to obtain a soybean germinated embryo extract.

Then, the soybean germinated embryo extract was applied to an UPLC (Ultra Performance Liquid Chromatography) QTOF-mass spectrometer to select major compounds.

As a result, it was confirmed that a large number of soya saponin compounds represented by the compounds 1 to 16 were present in the above extract. Among them, soybean saponins of the following compounds 13 to 16 are present in the germinated germinated embryo of the present invention, and (E) - ((2R, 3S, 4S, 5R, 6S) -3,4,5-trihydroxy-6- (3- (4-hydroxyphenyl) -4-oxo-4H-chromen-7-yloxy) -tetrahydro- enoate and -Hydroxy-2- (4-hydroxyphenyl) -4-oxo-4H-chromen-7-yl 6-O - [(2E) -2-butenoyl] hexopyranoside exist. Respectively. The above-mentioned soy saff saponins are listed in Table 1 below.

Compound No. Soya saponin compound name Molecular Weight One Soyasaponin Aa 1364 2 Soyasaponin Ab 1436 3 Soyasaponin Ac 1420 4 Soyasaponin Ae 1202 5 Soyasaponin Af 1274 6 Soyasaponin Ba 958 7 Soyasaponin Bb 942 8 Soyasaponin Bc 912 9 Soyasaponin Bd 956 10 Soyasaponin Be 940 11 Soyasaponin βg 1068 12 Soyasaponin beta a 1038 13 Streptococcus Ag 1171 14 Name of last name 1389 15 Soyasaponin Ah 1243 16 geneasaponin γg 921

Example  1. Beans Germination embryo  Evaluation of cytotoxicity of extracts

To confirm the safety of the soybean germinated embryo extract obtained according to Preparation Example 1, the cytotoxicity of the extract of hepatocyte strain HepG2 was evaluated.

Specifically, soybean germinated embryo extracts were prepared at a concentration of 50, 100, 200, 300, 400 and 500 ㎍ / mL, and treated with HepG2 hepatocyte and cultured for 24 hours or 72 hours. After the completion of the incubation, the water-insoluble formazan formed by the addition of the MTT solution was dissolved in a dimethyl sulfoxide solution, and the optical density (OD value) of the dissolved formazan at 595 nm was measured. The relative cell viability (%) was assessed by measurement.

As a result, as shown in FIG. 1, the soybean germinated embryo extract did not show cytotoxicity at all concentrations, and it was confirmed that the hepatic cell proliferation ability was rather improved as the concentration increased. Thus, the soybean germinated embryo extract of the present invention was found to be a safe substance free from harm to the human body, and it was found that lipid metabolism was positively influenced by promoting the proliferation of hepatocytes carrying lipid metabolism.

Example  2. Soy beans for lipid metabolism Germination embryo  Analysis of the effect of extracts

Example  2-1. Soybeans for HDL lipid metabolism Germination embryo  Analysis of the effect of extracts

In order to evaluate the therapeutic effect of the extract on hyperlipidemia, the effect of soybean germinated embryo extract on cholesterol composition of an animal model induced by hyperlipidemia by surgically removing ovaries was analyzed. After menopause, estrogen, which is a female hormone, is decreased and HDL is decreased. Therefore, the possibility of metabolic diseases including hyperlipemia is increased.

Specifically, 6-week-old male C57BL / 6 (Samtaco Bio, Osan, Korea) was used for the experiment. Prior to the start of the experiment, the purchased mice were fed a 45% fat-derived high fat diet of total calories to induce hypercholesterolemia. The breeding environment was controlled by aseptic system, and automatic lighting and lighting were operated at intervals of 12 hours. All animal test methods used in the present invention were in accordance with the animal test regulations and the experimental methods approved by the animal experiment ethics committee.

In order to investigate the effect of soybean germinated embryo extract on lipid metabolism, blood samples were collected by performing ocular blood collection once a week and four times every week for 3 weeks. Using a COBAS C111 blood analyzer, Blood analysis was performed. Blood samples were withdrawn for 12 to 15 hours, and anesthetized with avertin anesthetics. Approximately 200 μl of blood was collected, and centrifuged plasma was used for the experiment.

As a result, as shown in FIG. 2, the ratio of total cholesterol to HDL (total Chol / HDL ratio), which is an indicator of blood lipid metabolism, was higher in the test group administered with the extract than in the negative control (OVX) ). This effect was better as the concentration of the extract increased and the concentration of HDL was increased by about 155% in the test group administered with the high concentration of the extract (5 mg / kg / day) as compared to the negative control group.

Also, as shown in FIG. 3, it was confirmed that the test group administered with the extract reduced the ratio of triglyceride to HDL (Trig / HDL ratio) compared to OVX. In addition, it was confirmed that the above extract was also effective when administered at a low concentration (5 mg / kg / day).

In addition, the HDL-cholesterol content of OVX was 75 mg / dl as shown in FIG. 4 showing the HDL-cholesterol content in the blood, and 76.3 mg / dl and 85.3 mg / dl of the 0.1 mg, mg / dl and a cholesterol content of 81.5 mg / dl, indicating that the serum HDL-cholesterol content was increased compared to OVX which was 75 mg / dl.

From the above results, it was found that the soybean germinated embryo extract of the present invention can remove unnecessary cholesterol in vivo by increasing the concentration of HDL-cholesterol in the blood.

Example  2-2. Soybeans for LDL lipid metabolism Germination embryo  Analysis of the effect of extracts

As the soybean germinated embryo extract increased the HDL concentration in Example 2-1, the effect of the extract on LDL lipid metabolism was analyzed.

Specifically, the soybean germinated embryo extract was administered to an animal model inducing hyperlipidemia according to the method of Example 2-1, and the concentration of LDL contained in blood of the animal was analyzed.

As a result, as shown in FIG. 5, it was confirmed that the test group administered with the extract showed no significant difference from the ratio of LDL to HDL (LDL / HDL ratio) compared with the negative control (OVX) induced by hyperlipemia due to menopause Respectively.

From the above results, it can be seen that the soybean germinated embryo extract of the present invention does not participate in the lipid metabolism of LDL, but participates in the lipid metabolism which increases the HDL concentration, thereby showing the effect of eliminating unnecessary cholesterol in vivo.

From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are to be considered in all respects as illustrative and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.

Claims (13)

A pharmaceutical composition for preventing or treating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof.
The method according to claim 1,
Wherein the soybean germinated embryo is obtained by germinating the embryo isolated from the soybean.
The method according to claim 1,
Wherein the extract is obtained by extracting the soybean germinated embryo with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
The method according to claim 1,
Wherein the fraction is obtained by fractionating the extract with water, a lower alcohol having 1 to 4 carbon atoms, a non-polar solvent, or a mixed solvent thereof.
The method according to claim 1,
Wherein said extract is selected from the group consisting of Soyasaponin Aa, Soyasaponin Ab, Soyasaponin Ac, Soyasaponin Ae, Soyasaponin Af, Soyasaponin Ba, Soyasaponin Bb, Soyasaponin Bc, Soyasaponin Bc, Soyasaponin Be, Soyasaponin Be, Soyasaponin βg, Soyasaponin βa, Soyasaponin Ag, ≪ / RTI > wherein the composition comprises at least one soy saxaponin selected from the group consisting of < RTI ID = 0.0 >
The method according to claim 1,
Wherein the extract increases HDL (high density lipoprotein).
The method according to claim 1,
Wherein the metabolic disorder is cardiovascular disease or dyslipidemia.
8. The method of claim 7,
Wherein the cardiovascular disease is selected from the group consisting of hypertension, ischemic heart disease, coronary artery disease, angina pectoris, myocardial infarction, arteriosclerosis, arrhythmia, cerebrovascular disease and stroke.
8. The method of claim 7,
Wherein said dyslipidemia is selected from the group consisting of hyperlipidemia, hypercholesterolemia and hypertriglyceridemia.
The method according to claim 1,
Wherein the composition further comprises a pharmaceutically acceptable carrier, excipient or diluent.
10. A method for preventing or treating metabolic diseases, comprising administering the composition of any one of claims 1 to 10 to a subject other than a human.
A food composition for preventing or ameliorating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof.
A feed composition for preventing or ameliorating a metabolic disease comprising a soybean germinated embryo extract or a fraction thereof.

Images